AMGN - Amgen Inc.
| Previous Close | 201.92 |
| Open | 203.33 |
| Bid | 199.50 x 900 |
| Ask | 204.64 x 1100 |
| Day's Range | 201.04 - 204.33 |
| 52 Week Range | 163.31 - 210.19 |
| Volume | 3,094,991 |
| Avg. Volume | 3,109,927 |
| Market Cap | 129.916B |
| Beta (3Y Monthly) | 1.23 |
| PE Ratio (TTM) | 63.55 |
| EPS (TTM) | 3.21 |
| Earnings Date | Jan 29, 2019 |
| Forward Dividend & Yield | 5.80 (2.87%) |
| Ex-Dividend Date | 2019-02-14 |
| 1y Target Est | 205.05 |
- Zacks•4 hours ago
Top Analyst Reports for Bank of America, Merck & Netflix
Top Analyst Reports for Bank of America, Merck & Netflix
- Zacks•7 hours ago
Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks•9 hours ago
What's in Store for Bristol-Myers (BMY) in Q4 Earnings?
Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.
- Zacks•10 hours ago
Biogen (BIIB) Q4 Earnings Coming Up: What's in the Cards?
While sales of Biogen's (BIIB) MS franchise are expected to be stable in the fourth quarter that of Spinraza are likely to increase.
- Motley Fool•yesterday
Which Big Pharma Stocks Lose Most in a War on Drug Price Hikes?
The answer: It's complicated.
- Markit•2 days ago
See what the IHS Markit Score report has to say about Amgen Inc.
# Amgen Inc ### NASDAQ/NGS:AMGN View full report here! ## Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. ## Money flow ETF/Index ownership | Negative ETF activity is negative and may be weakening. The net inflows of $7.41 billion over the last one-month into ETFs that hold AMGN are among the lowest of the last year and appear to be slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. AMGN credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•3 days ago
Amgen (AMGN) Gains But Lags Market: What You Should Know
Amgen (AMGN) closed at $203.70 in the latest trading session, marking a +0.88% move from the prior day.
- Simply Wall St.•3 days ago
Should You Buy Amgen Inc. (NASDAQ:AMGN) For Its Dividend?
Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. Historically, Amgen Inc. (NASDAQ:AMGN) has paid a dividend to shareholders. Read More...
- Investor's Business Daily•4 days ago
FDA Committee Recommends Amgen Drug — But A Key Question Lingers
A Food and Drug Administration committee voted late Wednesday to recommend Amgen's osteoporosis treatment — but to a narrow population. Amgen stock rose Thursday.
- Zacks•4 days ago
Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod
Amgen (AMGN) gets positive vote from a FDA panel for osteoporosis candidate, Evenity.
- Benzinga•4 days ago
The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...
- Reuters•5 days ago
Amgen's postmenopausal osteoporosis drug wins FDA panel backing
An advisory panel to the U.S. Food and Drug Administration said on Wednesday that benefits of Amgen Inc's osteoporosis treatment for postmenopausal women at high risk for fracture outweighed its risks and overwhelmingly voted for the drug's approval. The panel voted 16-1 in favor of the monthly injection developed jointly with Belgium-based UCB SA. The drug, Evenity, helps reduce the risk of fracture by increasing bone formation and inhibiting break down of bone minerals. The panel, however, raised concerns of cardiovascular safety risks linked to the drug, which FDA staff reviewers on Monday had cited as the main reason for convening the panel meeting.
- PR Newswire•5 days ago
Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 16, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced strong support from the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) for the approval of EVENITY™* (romosozumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture after reviewing safety and efficacy data from the pivotal Phase 3 studies. "We are pleased with the Committee's recommendation to approve EVENITY for the treatment of postmenopausal women with osteoporosis at high risk for fracture," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
- Zacks•5 days ago
6 Reasons Why You Should Buy Eli Lilly (LLY) Stock in 2019
Here are five reasons which investors may consider while investing in Lilly's (LLY) stock.
- Benzinga•5 days ago
The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...
- Investor's Business Daily•6 days ago
Here's How The Government Shutdown Will Affect These Medical Stocks
The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.
- InvestorPlace•6 days ago
3 of the Top Big Pharma Stocks to Buy Now
The JPMorgan (NYSE:JPM) healthcare conference has brought greater awareness to the positive developments ahead for pharmaceutical stocks. Sure enough, the healthcare sector is up 1.3% Tuesday, with pharmaceutical stocks gaining a 1%. And although Big Pharma stocks are up because of the event, aided by a broad market rebound, there are still undervalued stocks in wider healthcare space. * 10 Growth Stocks With the Future Written All Over Them So what are the best stocks in Big Pharma that investors should pick up? The following pharmaceutical companies all have a track record of strong management, high-value product portfolios, and are on pace for continued growth in 2019. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock ### AbbVie (ABBV) AbbVie Inc. (NYSE:ABBV) recapped its many achievements since becoming a public company in 2013. In that time, the company followed through on its mission to create an innovation-driven, patient-focused biotech company. Its revenue growth, which accelerated last year, is proof of its outstanding execution of delivering on new medicines. 2018 Achievements and Outlook: AbbVie expects to deliver on strong growth again this year. Even with biosimilars bringing more competition to its more than $6 billion HUMIRA business, it will ramp up its HCV business in 2018 and will make big investments this year to support new product launches. Imbruvica and Venclexta are two leading mechanisms in the biosimilars that will drive AbbVie's future growth. These investments, or operating costs as seen on the income statement, will pay off as it supports growth over the next decade. Growth Products: AbbVie's hematology and oncology franchise is already annualizing over $4 billion and is growing in the double-digit rates. Upadacitinib and risankizumab, if approved, will come to market later this year and add to revenue. Management affirmed its confidence in the business by authorizing a $5 billion share buyback. Investors interested in ABBV stock should note the upcoming $1.07 dividend. The stock trades ex-dividend on Jan. 14. Source: Shutterstock ### Regeneron Pharmaceuticals (REGN) Regeneron Pharmaceuticals (NASDAQ:REGN) is trending near 52-week highs for good reason. Its atopic dermatitis drug, Dupixent, has a strong prescription growth rate. Patients, despite the costs, are staying with the medication. Eyelea is another source of revenue. And Regeneron is now developing CAR-T therapies. CAR-T Science: Regeneron is effectively disconnecting the CAR-T cell from the CD28 system. In doing so, it will allow its scientists to mix and match them. By having combinatorial specificity, it is possible to get better targeting and higher efficacy for treatments. In the non-small cell lung cancer space, where Keytruda failed, Regeneron hopes its agent is at least as effective as Merck's (NYSE:MRK). * 10 A-Rated Stocks the Smart Money Is Piling Into Core Drivers: Regeneron's core revenue drivers continue to give investors confidence. As mentioned, Dupixent is working out very well for patients. In its last quarter, the drug's global sales were $260 million, or nearly $1 billion annualized. The drug will also treat asthma. Plus, the company has positive data in eosinophilic asthma for reductions in the exacerbations for pulmonary function tests. Given the market size for patients suffering from asthma, Regeneron's revenues are likely to grow at a faster pace than the market expects. Source: Shutterstock ### Amgen (AMGN) Amgen Inc. (NASDAQ:AMGN) highlighted its double-digit earnings per share growth targets at the JPMorgan conference. It will get there by improving its operating margin from 38% to 52%-54%. Saving $1.5 billion will give it the room it needs to raise its return on capital to its shareholders while continuing on its transformation. Growth Drivers: Amgen will launch nine new products in two therapeutic areas. It already increased its global presence from 50 countries (in 2011) to over 100 at the end of last year. Its high R&D investments include those in the genetics space. In particular, deCODE Genetics in Iceland is impressive because it has 1 million people outside of Iceland who are part of the effort. It also ended the year with 500,000 patients in the U.S. who are available to study genotypically and phenotypically. Products: Amgen has six cancer medicines that are in the early stages of product development. Drugs in this space make $4 billion in revenues for Amgen and grew in the double-digit rates in the last twelve months. Looking ahead, Amgen expects to have a strong portfolio of first-in-class molecules. With biospecifics, small molecules, large molecules, its BiTE platform and CAR-Ts, Amgen has the potential to exceed its own growth goals. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies That Could Post Decelerating Profits * 10 A-Rated Stocks the Smart Money Is Piling Into * Mizuho: 7 Long-Term Value Stocks to Buy Now Compare Brokers The post 3 of the Top Big Pharma Stocks to Buy Now appeared first on InvestorPlace.
- Markit•6 days ago
See what the IHS Markit Score report has to say about Amgen Inc.
# Amgen Inc ### NASDAQ/NGS:AMGN View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $13.30 billion over the last one-month into ETFs that hold AMGN are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. AMGN credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Investor's Business Daily•7 days ago
Pharma Stocks Topple After House Dems Launch Drug-Pricing Probe
House Democrats launched an investigation into a dozen pharmaceutical companies on Monday, focusing on drug prices and prompting shares to topple. AstraZeneca and Novo Nordisk fell hard.
- Investor's Business Daily•7 days ago
Will Biogen Jump On This Biotech Stock Amid Buying Spree?
Alder Biopharmaceuticals could eventually capture 15%-20% of the market for migraine prevention, an analyst said Monday, suggesting the biotech stock might be a good fit for giant Biogen.
- Reuters•7 days ago
U.S. lawmaker launches investigation into pharma drug pricing
A top U.S. lawmaker launched an investigation into pharmaceutical industry pricing practices on Monday, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Representative Elijah Cummings, who chairs the House Oversight Committee, sent letters to 12 drugmakers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement.
- CNBC•7 days ago
House Democrats launch drug-pricing probe into a dozen major health-care companies
AbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
- Zacks•7 days ago
Is Amgen (AMGN) Stock Outpacing Its Medical Peers This Year?
Is (AMGN) Outperforming Other Medical Stocks This Year?
- Zacks•7 days ago
What's in Store for Merck in 2019 After a Solid Run in '18?
Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
- Zacks•7 days ago
Here's Why You Should Invest in Illumina (ILMN) Stock Now
Illumina's (ILMN) product launches continue to contribute to the top line. The company's recent broadening of genotyping sequencing line buoys optimism.
